## IONS: Ionis Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.7% below STRENGTH zone (3.0-6.0%); PEG 25.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($76.38)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)**
- Source: Business Wire | 20251203T042137 | Bullish | Relevance: 98%
- Ionis Pharmaceuticals, Inc. has announced that the U.S. FDA granted Breakthrough Therapy designation for zilganersen, an investigational medicine for Alexander disease (AxD), a rare and often fatal neurological condition. This designation aims to expedite the review process for zilganersen, which demonstrated clinically meaningful stabilization in a pivotal study. Ionis plans to submit a new drug application (NDA) in Q1 2026.

**2. Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and IDEAYA Biosciences (IDYA)**
- Source: The Globe and Mail | 20251203T042137 | Bullish | Relevance: 98%
-  Two healthcare companies, Ionis Pharmaceuticals (IONS) and IDEAYA Biosciences (IDYA), recently received bullish sentiments from analysts. Myles Minter from William Blair reiterated a Buy rating on Ionis, and Charles Zhu from LifeSci Capital maintained a Buy rating on IDEAYA. Both companies have an analyst consensus of Strong Buy.

**3. Ionis Pharmaceuticals stock hits 52-week high at 82.97 USD**
- Source: Investing.com | 20251204T042137 | Bullish | Relevance: 98%
- Ionis Pharmaceuticals (IONS) stock reached a 52-week high of $82.97, reflecting a significant upward trend with a 122.91% increase over the past year and a market capitalization exceeding $13 billion. The company's growth is driven by positive developments in its RNA-targeted therapies pipeline and strategic partnerships, bolstering investor confidence despite not being profitable in the last twelve months. Recent FDA Breakthrough Therapy designations and a positive European review for its drugs further indicate strong progress and potential for continued market momentum, with analyst price targets ranging from $47 to $116.76.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | B of A Securiti | $97 | $86 | +13% |
| 2025-11-10 | HC Wainwright & | $110 | $100 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | B of A Securiti | main | Buy |
| 2025-11-10 | HC Wainwright & | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 13 ($8.92M) |
| Sells | 21 ($5.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.1% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- FMR, LLC: 14.6% (+0.2%)
- Vanguard Group Inc: 10.2% (-1.4%)
- T. Rowe Price Invest: 8.1% (-18.0%)
- Capital World Invest: 7.8% (+1.5%)
- Blackrock Inc.: 6.5% (-4.1%)

### Key Risks

1. Insider selling cluster: $5.9M in recent transactions.
2. Valuation stretched: PEG 25.7x requires aggressive growth execution.
3. Elevated short interest (11.6%): bears positioning against stock.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 25.70 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.8x). Analyst sentiment positive (2 raises, avg +11%). Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $12.8B |
| Beta | 0.30 |
| 52W Range | $23.95 - $83.61 |
| Short Interest | 11.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 25.70 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 3.2% to -0.7% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.7pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.73% (CS: 48) | Neutral |
| RSI_14 | 67.4 | Neutral |
| MACD Histogram | 0.33 | Bullish |
| vs SMA20 | 1.065x | Above |
| vs SMA50 | 1.116x | Above |
| vs SMA200 | 1.719x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $81.68
- **Stop Loss:** $76.38 (6.5% risk)
- **Target:** $86.98 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 94
- **Position Value:** $7,677.92
- **Portfolio %:** 7.68%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.20)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.05 | $-0.61 | +41.8% |
| 2025Q2 | $0.16 | $0.85 | +415.1% |
| 2025Q1 | $-1.03 | $-0.92 | +10.4% |
| 2024Q4 | $-0.84 | $-0.43 | +49.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*